SCHEMBL5460000

SCHEMBL5460000

CC(C)(C)OC(=O)c1ccc(NC(=O)c2cccc(/C=C3/SC(=O)N(Cc4ccc(Cl)c(Cl)c4)C3=O)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 6/20 0.51
▸ ACP1 P24666 6/20 0.51
▸ ENPP2 Q13822 4/20 0.50
▸ KDR P35968 3/20 0.50
▸ PTPN2 P17706 1/20 0.45
▸ PIM1 P11309 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ STAT3 P40763 1/20 0.45
▸ PPARG P37231 1/20 0.44
▸ PKM P14618 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460002 1.00 PTPN1 (0.51) PTPN1ACP1ENPP2KDRPTPN2
SCHEMBL5457292 0.90 ENPP2 (0.58) PTPN1ACP1ENPP2PTPN2PIM1
SCHEMBL5457289 0.90 ENPP2 (0.58) PTPN1ACP1ENPP2PTPN2PIM1
SCHEMBL5455170 0.88 PTPN1 (0.64) PTPN1ACP1ENPP2KDRPTPN2
SCHEMBL5787070 0.88 PTPN1 (0.64) PTPN1ACP1ENPP2KDRPTPN2
SCHEMBL5468714 0.84 ENPP2 (0.54) PTPN1ACP1ENPP2KDRPTPN2
SCHEMBL5468711 0.84 ENPP2 (0.54) PTPN1ACP1ENPP2KDRPTPN2
SCHEMBL5464100 0.82 ENPP2 (0.49) PTPN1ACP1ENPP2PTPN2MEN1
SCHEMBL5464096 0.82 ENPP2 (0.49) PTPN1ACP1ENPP2PTPN2MEN1
SCHEMBL5470534 0.81 ENPP2 (0.55) PTPN1ACP1ENPP2PTPN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 PTPN1 3264/4885ACP1 254/4885ENPP2 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback